23andMe restructures, plans to cut 75 jobs

Genetic testing and drug development company 23andMe said it will cut 75 jobs — about 9% of the company's workforce — as part of a restructuring effort. 23andMe Holding Co. (NASDAQ: ME), which went public in a $3.5 billion "blank check" merger in 2021 with a special purpose acquisition company founded by billionaire Richard Branson, said in a Securities and Exchange Comm ission filing Friday that the restructuring is designed to "align our workforce with the company's strategy" and reduce operating…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news